Moneycontrol Be a Pro
Get App
SENSEX NIFTY
Vivimed Labs > Company History > Pharmaceuticals > Company History of Vivimed Labs - BSE: 532660, NSE: VIVIMEDLAB
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - Vivimed Labs

Vivimed Labs

BSE: 532660|NSE: VIVIMEDLAB|ISIN: INE526G01021|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Nov 21, 15:57
12.98
0.61 (4.93%)
VOLUME 15,905
LIVE
NSE
Nov 21, 15:57
13.00
0.65 (5.26%)
VOLUME 212,739
Company History - Vivimed Labs
The Company was originally promoted by Mr. A. M. Rao and incorporated
 as Emgi Pharmaceuticals & Chemicals Private Limited on September 22,
 1988 with Registrar of Companies of Karnataka, Bangalore. On Mr.
 Rao's
 accidental death the Company was put for a sale. In 1989 Mr. Santosh
 Varalwar and Mr. Subhash Varalwar acquired Emgi Pharmaceuticals and
 Chemicals Limited and commenced manufacturing of Bulk Drugs in 1991.
 Both the present promoters are professionals with more than a decade
 of
 experience in Chemicals and Pharmaceutical Industry. The Company was
 converted into a Public Limited Company on April 4, 1994. The name
 of
 the Company has been changed to Vivimed Labs Limited on April 22,
 1997.
 The name of the Company has been changed to incorporate present
 Promoter's initials in the Company's name.
 
 The Company's manufacturing Unit is located at Bidar, Karnataka,
 where
 it was originally engaged in the manufacturing of Active
 Pharmaceutical
 Ingredients (APIs) and Bulk Drugs like Ibuprofen etc. However, due
 to
 downward price movement in the products of the Company during 1995,
 it
 gradually moved over to manufacturing Specialty Chemicals and
 cosmetic
 ingredients like Triclosan, Avis etc. catering to global and
 domestic
 markets.
 
 Vivimed started production of Triclosan with a very small capacity of
 5
 MT p.a, in the year 1999 and increased its capacity to 225 MT p.a.
 over
 a period of next 5 years. The production capacity has been doubled
 by
 adding one more production block in March 2004. The Company
 currently
 employs over 250 personnel including contract laborers.
 
 Vivimed's Turnover has grown from Rs. 751.85 lacs in FY1999 to Rs.
 4,042.55 lacs in FY2004 and its Net profit grew from Rs. 15.26 lacs
 in
 FY1999 to Rs. 400.28 lacs in FY2004. The Turnover of the Company for
 6
 months period ended September 30, 2004 is Rs. 2322.60 Lacs and Net
 Profit is Rs.249.24 lacs. As at September 30, 2004, the Networth of
 the
 Company was Rs. 1850.15 lacs.
 
 The Company has ISO 9001:2000 certification for its Quality
 Management
 System related to manufacturing process and marketing aspects.
 Further,
 the Company is in the process of obtaining ISO 14001 certification
 for
 Environmental Management System for which two Audits have already
 been
 completed.
 
 Major events In -the history of the Company is given below:
 
 Year   Event
 
 1988 & * Incorporated on September 22, 1988
 1989   * Death of original promoter Mr. A. M. Rao
        * Acquired by Mr. Santosh Varalwar and Mr. Subhash Varalwar
 1990   * Commenced production of Non-Steroidal Anti-Inflammatory 
           Drug (NSAID) - IBUPROFEN.
 1994   * Diversification and Expansion of Product mix by adding 
          other APIs viz. Chlorzoxazone (Skeletal disorders), 
          Nalidixic Acid (Anti-diarrheas) and Flucanazole
 (Anti-fungal).
 1995   * Diversification into specialty chemicals by production of 
          Triclosan.
 1996   * R&D was commenced with facilities having an integrated 
          instrumentation for organic synthesis, Microbiology and 
          pre-formulation studies.
 1997   * Process Innovation of Anti-bacterial and clearance of 
          innovative route of synthesis for Triclosan.
        * Grant of patent for VIV-20 (Triclosan) by the Indian 
          Patents Office.
 1998-  * Qualified for supply to Unilever's Asian locations after 
 99       Audit of manufacturing facility by a team of Unilever Plc.
 
        * Triclosan customer base expanded to UK, France, Germany as 
          well as domestic market;
 
 2002   * Approved by Unilever group Companies in Asian/Middle & 
          Far East Companies for usage of Enamel Protective Agent 
          manufactured by the Company in their oral care
 formulations.
 
        * Developed Anti-fungal for usage in High-end cosmetic and 
          pre-formulation blends.
 
        * Vivimed emerges as a second chemical Company located outside
 
          USA/Europe to get the US EPA's registration for Triclosan 
          as 99% ingredient.
 
        * Vivimed's Quality Management System gets ISO 9001:2000 
          certification.
 
 2003   * Signed Confidential Sale Agreement with HLL for R&D, 
          scaling up and commercialization of product coded as A123.
 
        * Commencement of EMS Audit for ISO 14001 certification.
 
 2004   * Introduced new products for anti-dandruff and skin care 
          application
 
        * Triclosan production capacity increased from 225 MT p.a. 
          to 480 MT p.a.
 
        * Developed novel synthetic process to manufacture a premium 
          Anti-oxidant and Anti-cancer molecule branded as VINTOX
 
 2005   * The Company has received the State Award for Excellence in 
          Exports (SSI GOLD) from Karnataka State Government for 
          excellence in exports
 
        * The Company has received 1 star export house status in
 2005.
 
 2009
 
 - Vivimed Labs Ltd has informed BSE that Mr. Y Krishna has been
 appointed as an Additional Director on the Board of the Company with
 effect from June 30, 2009 in the Board Meeting of the Company held on
 June 30, 2009.
 
 2010
 
 - Vivimed Labs Ltd has appointed Mr. Nixon Patel as an Additional
 Director of the Company with effect from June 28, 2010.
 Mr. Nixon Patel has been appointed as an Independent Director on the
 Board.
 
 2011
 
 -Vivimed Labs Incorporation of Foreign Subsidiaries namely, Vivimed
 Labs Mauritius Ltd., Mauritius, Vivimed Labs UK Ltd., UK and Vivimed
 Labs Spain, SL, Spain.
 
 -Vivimed Labs has accquired majority Stake in Octtantis Nobel Labs
 Private Ltd.
 
 -Vivimed Labs Acquired equity stake in Klar Sehen Pvt. Ltd.
 
 -Vivimed Labs Acquired Uquifa Spain and Uquifa Mexico
 
 2012
 
 -Vivimed launch Nisarg Soapnut at in-cosmetics, Barcelona.
 
 -Mr. K. Yugandhar has been appointed as Company Secretary of the
 company
 
 2013
 -Vivimed acquires a US FDA approved formulation manufacturing
 facility.
 -Vivimed are Exhibiting at HPCi - Mumbai.
 
 2014
 -Vivimed receives the PIC/S GMP approval for one of its
 pharmaceuticals manufacturing facilities in Hyderabad.
 -Vivimed Labs - Grant of Options under Vivimed Labs ESOS 2010.
 
 2016
 -Vivimeds FDF facility in Alathur completed successful USFDA
 inspection
 -Vivimed launch Jarocol Sapphire Blue
 
Source : Dion Global Solutions Limited
Quick Links for Vivimed Labs
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.